A pilot study (NCT04393506) was conducted to explore the combined use of the PD‐1 inhibitor camrelizumab and VEGFR2 inhibitor Apatinib in LA‐HNSCC [88]. Here, PDCD1 is linked to head and neck squamous cell carcinoma.